Atara Biotherapeutics Company
Atara Biotherapeutics is a company that develops treatments for cancer, autoimmune, and viral diseases using off-the-shelf, allogeneic T-cell immunotherapy. They collaborate with academic institutions and have expertise in scientific, clinical, regulatory, and manufacturing fields. Their pipeline includes tab-cel, which is in Phase 3 development for patients with Epstein-Barr virus-associated post-transplant lymphoproliferative disorder (EBV+ PTLD) and other EBV-associated hematologic malignancies and solid tumors.
Connections from
Industry:
PharmTech
Founded Date:
2012
Headquarters:
Zug